US Patent No: 7,413,750

Number of patents in Portfolio can not be more than 2000

Process for producing solid oral dosage forms with sustained release of active ingredient

ALSO PUBLISHED AS: 20020012701

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-soluble polymers or lipophilic additives and, where appropriate, other conventional excipients, wherein this mixture or parts of this mixture are granulated by heating to from 40.degree. C. to 130.degree. C., and the granules are, after admixture with conventional excipients, subsequently tabletted.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BASF SELUDWIGSHAFEN1828

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ascherl, Hermann Dirmstein, DE 23 91
Flick, Dieter Bohl-Iggelheim, DE 10 15
Kolter, Karl Limburgerhof, DE 117 362

Cited Art Landscape

Patent Info (Count) # Cites Year
 
BASF AKTIENGESELLSCHAFT (2)
4,801,460 Preparation of solid pharmaceutical forms 117 1987
6,635,279 Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production 31 2001
 
AWD.PHARMA GMBH & CO. KG (1)
6,103,264 Process for preparing a controlled release composition 6 1998
 
DUQUESNE UNIVERSITY OF THE HOLY GHOST, A CORP. OF PA. (1)
5,169,645 Directly compressible granules having improved flow properties 91 1989
 
FARVALSA A.G. (1)
4,837,032 Theophylline sustained release tablet 18 1986
 
HEXAL AG (1)
5,874,107 Sustained release tablet containing diclofenac-Na and methylhydroxypropyl-cellulose as a sustained release agent 1 1996
 
NOVARTIS AG (1)
5,403,593 Melt granulated compositions for preparing sustained release dosage forms 32 1992
 
SCHWARZ PHARMA AG (1)
5,453,283 Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation 21 1993
 
TANABE SEIYAKU CO., LTD. (1)
5,389,380 Sustained release pharmaceutical preparation and process for preparing the same 10 1993

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
EISAI R&D MANAGEMENT CO., LTD. (2)
8,481,565 Method for stabilizing anti-dementia drug 0 2005
8,507,527 Method for stabilizing anti-dementia drug 0 2010

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 19, 2016
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 19, 2020
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00

Full Text

 
loading....